Petition to the DEA and FDA to Classify the Drug Gabapentin as a Schedule V Controlled Substance
Public Citizen petitioned the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) to add the prescription drugs gabapentin and gabapentin enacarbil to schedule V under the Controlled Substances Act to more tightly monitor and regulate use of these drugs because they are increasingly being misused, abused, and diverted, leading to dependence and overdose deaths.
February 9, 2022, FDA acknowledgment letter.
August 4, 2022, FDA interim response letter.
October 7, 2022, DEA letter accepting petition for filing for gabapentin only.
January 18, 2023, FDA final response letter.